Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Usage of Synaffix GlycoConnect, HydraSpace and toxSYN ADC technologies to enhance efficacy, tolerability and target engagement
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
The company uses iPS cells to develop treatments for diseases relating to the kidney
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Subscribe To Our Newsletter & Stay Updated
